Our Commitment

We continue to execute our two-pronged growth strategy–driving organic growth through market penetration and label expansion while also pursuing strategic acquisitions to expand our product portfolio. In 2024, we seized opportunities to expand our reach and further address critical unmet medical needs through the successful commercialization of AGAMREE^® and approval of a higher maximum daily dose for FIRDAPSE^® in the United States.

As we grow, we continue to uphold our rigorous quality standards, safety protocols, and active engagement with our patient community, as each of these efforts contributes to our ability to fulfill our commitment to delivering safe, accessible, and affordable treatments to patients with rare and difficult-to-treat diseases. Integral to these efforts is our Catalyst Pathways^® program, which offers personalized support and comprehensive patient services, such as educational resources, financial assistance, and patient community outreach opportunities. This is just one of the many ways we help eligible patients access the therapies they need, regardless of their ability to pay.

We recognize that our growth and success are deeply rooted in the well-being of our employees. We are committed to fostering meaningful engagement, career development opportunities, and comprehensive benefits to ensure each team member has the support needed to fulfill our mission of making a meaningful impact on the lives of those with rare diseases.

Beyond our workforce, we support our local communities through engagement, volunteering, and charitable giving. We also engage in efforts to promote fair and equal healthcare access–addressing the needs of underserved communities through our dedicated resource team of patients and employees.

Despite our limited footprint, which consists of a single corporate office and outsourced manufacturing, we continue to initiate actionable steps to enhance our environmental initiatives, reporting, and transparency for all stakeholders. As part of efforts to assess and manage our environmental impact, we calculate and report on our Scope 1 and 2 greenhouse gas emissions and have conducted a climate-related risks and opportunities assessment as aligned with Task Force on Climate-Related Financial Disclosures (TCFD) recommendations. These steps not only contribute to a holistic risk management approach but also translate to a better understanding of our environmental impacts and the role we play in supporting a sustainable future.

Our Code of Conduct and Business Ethics guides responsible and ethical business practices, supporting the long-term success of our business. Our Board of Directors plays a crucial role in overseeing our business strategy, promoting a culture that is rooted in integrity and accountability. As part of these efforts, we have integrated ESG principles into our corporate governance and risk management structures–enabling us to strengthen decision-making, manage risk, and generate sustainable value for our shareholders.